Prof. Dr. med. M. Kramer

Founder, managing director and shareholder (via ImmBiomed GmbH) of ImmBioMed Business Consultants GmbH & Co. KG.

Kramer 0904_1_bearbeitet Labor Michael Kramer was born 1958 in Jugenheim (Germany) and started his medical studies 1977 at Heidelberg University. 1985 he was board-certified as medical doctor and was promoted to M.D. by Heidelberg University. 1992 he was appointed Assistant Professor at Heidelberg University. 1999 he was board-certified for Laboratory Medicine and Medical Quality Management; in 2000 also for Transfusion Medicine. In December 1992 he was appointed as Adjunct Professor for Applied Immunology at Heidelberg University. Michael Kramer is married and has two children.

Career History

1979 – 1985 Student Assistant at the German Cancer Research Center in Heidelberg
1985 – 1987 Military Service at the Central Institute of the Medical Corps of the Germany Army in Koblenz
1987 – 1998 Various clinical and laboratory institutions at the Heidelberg University Medical Center; from 1992 – 1998 senior assistant at the Institute for Immunology of Heidelberg University and head of the Immuno-Pathology Laboratory
1999 – 2003 Managing Director of LYNX Therapeutics GmbH in Heidelberg; a subsidiary of Lynx Therapeutics Inc., Hayward, CA, USA
Since 2003 Founding and developing ImmBioMed Business Consultants GmbH & Co. KG

Scientific Awards

1985 Julius-Redel-Prize of the Medical Faculty of Heidelberg University
1989 Paul-Gersson-Unna-Prize of the German Dermatological Society
1998 Robert-Pfleger-Preis for Biomedical research

Selected Publications

Kramer, M.D., L. Binninger, V. Schirrmacher, H. Moll, M. Prester, G. Nerz, and M.M. Simon. 1986
Characterization and isolation of a trypsin-like serine protease from a long-term culture cytolytic T cell line and its expression by functionally distinct T cells.
J. Immunol. 136:4644-4651.

Simon, M.M., H. Hoschützky, U. Fruth, H.-G. Simon, and M.D. Kramer. 1986
Purification and characterization of a T cell specific serine proteinase (TSP-1) from cloned cytolytic T lymphocytes.
EMBO J. 5:3267-3274.

Kramer, M.D. and Simon M.M. 1987
Are proteinases functional molecules of T lymphocytes?
Immunology Today 8:140-142.

Kramer, M.D., U.E. Schaible, R. Wallich, S.E. Moter, D. Petzoldt, M.M. Simon. 1990
Characterization of Borrelia burgdorferi associated antigens by monoclonal antibodies.
Immunobiol. 181:357-366.

Schaible, U.E., M.D. Kramer, K. Eichmann, M. Modolell, C. Museteanu, and M.M. Simon. 1990
Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice.
Proc. Natl. Acad. Sci. USA 87:3768-3772.

Simon M.M., U.E. Schaible, R. Wallich, and M.D. Kramer. 1991.
A mouse model for Borrelia burgdorferi infection: approach to a possible vaccine against
Lyme disease.
Immunology Today 12:11-16.

Kramer, M.D. and J. Reinartz. 1993.
The autoimmune blistering skin disease bullous pemphigoid: The presence of plasmin/
2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
J. Clin. Invest. 92:978-983.

Reinartz J., R. Batrla, P. Boukamp, N. Fusenig, and M.D. Kramer. 1993.
Binding and activation of plasminogen at the surface of human keratinocytes.
Exp. Cell Res. 208:197-208.

Fuchs H., R. Wallich, M.M. Simon, and M.D. Kramer. 1994.
The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmino(gen) receptor.
Proc. Natl. Acad. Sci: USA 91: 12594-12598.

Moter, S.E., H. Hofmann, R. Wallich, M.M. Simon, and M.D. Kramer. 1994.
Detection of Borrelia burgdorferi sensu lato in lesional skin of erythema migrans and acrodermatitis chronica atrophicans by OspA-specific polymerase chain reaction.
J. Clin. Microbiol. 32:2980-2988.

Foekens J.A., F. Buessecker, H.A. Peters, U. Krainick, W.L.J. van Putten, and M.D. Kramer. 1995.
Plasminogen activator inhibitor-2 (PAI-2): prognostic relevance in 1012 patients with primary breast cancer.
Cancer Res. 55:1423-1427.

Fuchs H., M.M. Simon, R. Wallich, M. Bechtel, and M.D. Kramer. 1996.
Borrelia burgdorferi induces the secretion of pro-urokinase-type plasminogen activator by human monocytes.
Infect. Immun. 64:4307-4312.

Bechtel M. J., J. Rox, S. Inndorf, J. Reinartz, B. Schaefer, and M.D. Kramer. 1996.
Upregulation of cell surface-associated plasminogen activation in cultured keratinocytes by Interleukin-1beta and Tumor-Necrosis-Factor-alpha.
Exp. Cell. Res. 223:395-404.

Schaefer B., C. Jaeger, E. Drepper, and M.D. Kramer. 1996.
Plasminogen activation in bullous pemphigoid. Immunohistology revels uPA, uPA-R, and PAI-2 in lesional epidermis.
Autoimmunity 23:155-164.

Schaefer B.M., J. Reinartz, M.J. Bechtel, S. Inndorf, E. Lang, M.D. Kramer. 1996.
Dispase-mediated basal detachment of cultured keratinocytes induces urokinase-type plasminogen activator (uPA9 and its receptor (uPA-R, CD87).
Exp. Cell. Res. 228:246-253.

Schaefer M.D., C. Jaeger, and M.D. Kramer. 1996.
The plasminogen activator system in pemphigus vulgaris.
Br. J. Dermatol. 135:726-732.

Schott D., C.-E. Dempfle, P. Beck, A. Liermann, A. Mohr-Pennert, M. Goldner, P. Mehlem, H. Azuma, V. Schuster, A.-M. Mingers, H.P. Schwarz, and M.D. Kramer.1998
Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency.
New Engl. J. Med. 339:1679-1686.